The "Myopia and Presbyopia Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's ...
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ ...
The VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia is also enrolling patients. Top-line results are expected in the first half of 2025. The ...
CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash ...
Healthcare Asia on MSN4d
Global myopia and presbyopia treatment market to grow by $9.76b by 2028It is driven by the rising prevalence of these vision conditions. The global myopia and presbyopia treatment market is set to ...
Comfort was the name of the game when OT spoke with contact lens manufacturers and suppliers about recent trends and launches ...
Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients ...
You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...
Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. Following prepared remarks from ...
Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...
As CIIE provides us with a unique platform to engage with governments, academic institutions, industrial partners, and media, ...
Leerink raised the firm’s price target on Lenz Therapeutics (LENZ) to $36 from $32 and keeps an Outperform rating on the shares after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback